Theralux™ ATIR Feasible Strategy for Mismatched Stem Cell Transplantation
Kiadis Pharma B.V. has announced Phase I data suggesting that it’s investigational Theralux™-ATIR technology reduced the risk of acute graft-versus-host disease among blood cancer patients who received donor lymphocyte infusions (DLI) following mismatched stem cell transplantation. Data were presented during the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH).
Click here to read the full press release
More news
- Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 4-1-2011
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 6-1-2009
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board 11-12-2008
